On 01-14-2020, FDA released this alert of possible association of cancer with Lorcaserin:
FDA mentioned that at this time, the cause of the cancer is uncertain, and we cannot conclude that lorcaserin contributes to the cancer risk:
Randomized, double-blind, placebo-controlled clinical trial conducted in ~12,000 participants found that more patients taking lorcaserin were diagnosed with cancer compared to patients taking placebo.
Lorcaserin Mechanism of Action:
Stimulates 5HT2C receptor —> Stimulates POMC neuron —-> Releases alpha MSH —> acts on MC4R —> resulting in suppression of appetite.
- POMC = Pro-OpioMelanoCortin Neuron
- MSH = Melanocyte Stimulating Hormone
- MC4R = Melanocortin-4 Receptor
FDA-approved medication for weight loss in obesity:
- Phentermine (Adipex-P®)
- Orlistat (Xenical®)
- Lorcaserin (Belviq®)
- Liraglutide (Saxenda®)
- Phentermine/Topiramate (Qsymia®)
- Naltrexone/Bupropion (Contrave®)